3 ms·
Exactly. When you remove the patient group that experiences 90% of the severe cases, voila, your efficacy rate skyrockets. Until SOMEONE ELSE completes trials
by randcraw 6y ago
Exactly. When you remove the patient group that experiences 90% of the severe cases, voila, your efficacy rate skyrockets.
Until SOMEONE ELSE completes trials on that missing age 55+ cohort, this vaccine should be accepted ONLY for ages 0 to 54. And given its likely low efficacy (62%), NOT for anyone with co-morbidities.
- happymellon 6y agoThis statement is moronic. The vaccine has been tested on 55+. We are not doing a half initial dose because that hasn't been studied in detail.
- DanBC 6y ago> patient group that experiences 90% of the severe cases, 43% of the patients going into ICUs in the UK[1] are under 60 years old. Most of the patients going into ICUs (including the older people) needed no assistance in their day to day lives before going into ICU.
- Engineering-MD 6y agoBut that is also a selection bias. The very elderly or those who need lots of assistance in day to day lives or those with multiple comorbidities are much less likely to benefit from an ICU stay (ie they will likely die with or without support) so don’t get admitted at all.